Bi, WenyaZhang, MichaelWu, WinonaMei, YuDunn, Ian2016-08-092016Bi, Wenya Linda, Michael Zhang, Winona W. Wu, Yu Mei, and Ian F. Dunn. 2016. “Meningioma Genomics: Diagnostic, Prognostic, and Therapeutic Applications.” Frontiers in Surgery 3 (1): 40. doi:10.3389/fsurg.2016.00040. http://dx.doi.org/10.3389/fsurg.2016.00040.2296-875Xhttp://nrs.harvard.edu/urn-3:HUL.InstRepos:27822290There has been a recent revolution in our understanding of the genetic factors that drive meningioma, punctuating an equilibrium that has existed since Cushing’s germinal studies nearly a century ago. A growing appreciation that meningiomas share similar biologic features with other malignancies has allowed extrapolation of management strategies and lessons from intra-axial central nervous system neoplasms and systemic cancers to meningiomas. These features include a natural proclivity for invasion, frequent intratumoral heterogeneity, and correlation between biologic profile and clinical behavior. Next-generation sequencing has characterized recurrent somatic mutations in NF2, TRAF7, KLF4, AKT1, SMO, and PIK3CA, which are collectively present in ~80% of sporadic meningiomas. Genomic features of meningioma further associate with tumor location, histologic subtype, and possibly clinical behavior. Such genomic decryption, along with advances in targeted pharmacotherapy, provides a maturing integrated view of meningiomas. We review recent advances in meningioma genomics and probe their potential applications in diagnostic, therapeutic, and prognostic frontiers.en-USMini Reviewmeningiomagenomicsmolecular taxonomytargeted therapyprecision medicineJournal Article2016-08-0910.3389/fsurg.2016.00040